Neural stem cell‐derived factors inhibit the growth and invasion of U87 stem‐like cells in vitro

Abstract

Glioma is one of the most common and aggressive tumors in the brain. Significant attention has been paid to the potential use of neural stem/progenitor cells (NSCs/NPCs) as delivery vehicles to cure gliomas. However, whether the NSCs/NPCs or the factors they produced could make a contribution still remains to be seen. In this study, we focused on the inhibitory effects of the factors produced by NSCs/NPCs on the biological behavior of the glioma stem‐like cell in vitro. The human glioma cell line U87 was selected and the U87 stem‐like cells were addressed. After being cultured in the NSC condition medium (NSC‐CM), the viability and proliferation of U87 stem‐like cells were significantly reduced. The invasion of U87 stem‐like cells and the migration of U87 cells were also significantly decreased. However, no significant change was observed in regard to the astrocytic differentiation of U87 stem‐like cells. These indicated that NSCs/NPCs produced some factors and had an inhibitory effect on the growth and invasion but not the terminal differentiation of U87 stem‐like cells. It is worth paying attention to NSCs/NPCs as a high‐potential candidate for glioma treatment.

Human neural stem cells repress glioma cell progression in a paracrine manner by downregulating the Wnt/β‐catenin signalling pathway

“…Exosomal lncRNA PTENP1 mediates cell communication and exerts antitumour activity [ 14 ]. Numerous studies have shown that rat NSC‐CM‐induced antiglioma effects are related to the mitogen‐activated protein kinase (MAPK) [ 39 , 40 ] and PI3K/AKT signalling pathways [ 27 ]. The present study demonstrated that human NSC‐CM represses glioma cell progression by downregulating the Wnt/β‐catenin pathway, which is consistent with previous reports.…”

“…Inhibiting the effects of abnormal Wnt/β‐catenin signalling may be a vital step in preventing glioma progression. Rat embryonic neural stem/progenitor cell (NSC/NPC)‐conditioned medium inhibits U87 cell growth and invasion by downregulating β‐catenin expression [ 27 ]. However, the effects of human NSC‐CM on glioma cell progression remain unclear.…”

Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges

“…In another report, cultures containing U87 stem-like cells in contact with an NSC-conditioned medium showed low viability and multiplication of U87 cells without significant modulation of their astrocytic differentiation capacity. Moreover, the invasive and migratory functions of U87 stem-like cells were also reduced [60].…”

“…The continued assessment showed the presence of NPCs 20 days after the injection. The neuropathological study of the brains showed that the transplanted stem cells were exclusively in inflammatory regions of neurodegeneration and not in normal tissue, suggesting their potential role in the reversal of the inflammatory process [60]. Finally, the implementation of exogenous human NSCs into the dentate gyrus can also activate the production of endogenous NSCs [58].…”

Targeting the neural stem cells in subventricular zone for the treatment of glioblastoma: an update from preclinical evidence to clinical interventions

“…In another report, contact with NSCs conditioned medium containing U87 stem cells (a glioma cell line) showed a lower survival rate and proliferation of U87 cells, and no significant regulatory effect on astrocyte differentiation. In addition, the invasion and migration of U87 stem cells were also reduced [ 56 ]. These suggest that normal NSCs may play a direct role in GBM.…”